文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

第二剂COVID-19疫苗加强针在养老院居民中预防感染、住院或死亡的效果——19个州,2022年3月29日至7月25日

Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-09-30

学术、联邦和私营合作伙伴利用196家美国社区养老院的常规照护数据,评估已接种3剂COVID-19疫苗的养老院居民接种第二剂mRNA加强针的疫苗有效性(VE)。结果显示60天VE对SARS-CoV-2感染为25.8%,对重症COVID-19结局(住院或死亡复合终点)为73.9%,对COVID-19相关死亡为89.6%。

要点

  • 已接种3剂的养老院居民接种第二剂mRNA加强针后60天VE:感染25.8%、重症结局73.9%、死亡89.6%。
  • 研究期间主要流行Omicron亚变异株BA.2、BA.2.12.1及BA.4、BA.5。
  • 第二剂mRNA加强针较第一剂加强针提供额外保护,预防重症COVID-19结局。

核心结论

  • 在养老院居民中,第二剂mRNA COVID-19疫苗加强针在Omicron变异株流行期间较第一剂加强针提供了针对重症COVID-19结局的额外保护。

研究设计与样本

  • 学术、联邦和私营合作伙伴评估196家美国社区养老院的常规照护数据,估计已接种3剂COVID-19疫苗(2剂基础系列和1剂加强针)的养老院居民接种第二剂mRNA加强针的疫苗有效性。
  • 居民于2022年3月29日至6月15日期间接种第二剂mRNA加强针,随访至2022年7月25日。

主要发现

  • 第二剂mRNA加强针的60天VE对SARS-CoV-2感染为25.8%,对重症COVID-19结局(COVID-19相关住院或死亡的复合终点)为73.9%,对COVID-19相关死亡为89.6%。
  • 研究期间主要流行Omicron变异株B.1.1.529和BA.2的亚变异株BA.2和BA.2.12.1(2022年3月至6月)以及BA.4和BA.5(2022年7月)。

关键数值与推荐

  • 2022年3月29日,免疫实践咨询委员会(ACIP)推荐为年龄≥50岁且接种第一剂加强针≥4个月的成人及所有免疫功能低下者接种第二剂mRNA COVID-19疫苗加强针。
  • 2022年9月1日,ACIP投票推荐为所有年龄≥12岁且完成基础系列(使用单价疫苗)≥2个月者接种二价mRNA COVID-19疫苗加强针。

临床怎么用

  • 机构应继续确保养老院居民及时接种COVID-19疫苗,包括二价疫苗加强针,以预防重症COVID-19结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nursing home residents continue to experience significant COVID-19 morbidity and mortality (1). On March 29, 2022, the Advisory Committee on Immunization Practices (ACIP) recommended a second mRNA COVID-19 vaccine booster dose for adults aged ≥50 years and all immunocompromised persons who had received a first booster ≥4 months earlier.* On September 1, 2022, ACIP voted to recommend bivalent mRNA COVID-19 vaccine boosters for all persons aged ≥12 years who had completed the primary series using monovalent vaccines ≥2 months earlier (2). Data on COVID-19 booster dose vaccine effectiveness (VE) in the nursing home population are limited (3). For this analysis, academic, federal, and private partners evaluated routine care data collected from 196 U.S. community nursing homes to estimate VE of a second mRNA COVID-19 vaccine booster dose among nursing home residents who had received 3 previous COVID-19 vaccine doses (2 primary series doses and 1 booster dose). Residents who received second mRNA COVID-19 vaccine booster doses during March 29-June 15, 2022, with follow-up through July 25, 2022, were found to have 60-day VE of 25.8% against SARS-CoV-2 (the virus that causes COVID-19 infection), 73.9% against severe COVID-19 outcomes (a combined endpoint of COVID-19-associated hospitalizations or deaths), and 89.6% against COVID-19-associated deaths alone. During this period, subvariants BA.2 and BA.2.12.1 (March-June 2022), and BA.4 and BA.5 (July 2022) of the B.1.1.529 and BA.2 (Omicron) variant were predominant. These findings suggest that among nursing home residents, second mRNA COVID-19 vaccine booster doses provided additional protection over first booster doses against severe COVID-19 outcomes during a time of emerging Omicron variants. Facilities should continue to ensure that nursing home residents remain up to date with COVID-19 vaccination, including bivalent vaccine booster doses, to prevent severe COVID-19 outcomes.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. McConeghy KW, White EM, Blackman C, et al. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36173757. doi:10.15585/mmwr.mm7139a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。